Qbrexza

Drooling, peripheral muscarinic effects, cardiac vagal inhibitory reflexes + 16 more

Treatment

20 Active Studies for Qbrexza

What is Qbrexza

Glycopyrronium

The Generic name of this drug

Treatment Summary

Glycopyrronium, also known as NVA237 or glycopyrrolate, is a medication used to reduce secretions from sweat glands, the mouth, airways, and stomach. It is also used to reduce cardiac inhibitory reflexes and bronchoconstriction in Chronic Obstructive Pulmonary Disease (COPD). It was originally approved by the FDA in 1961 and is commonly prescribed as a first-line treatment for a variety of conditions, due to its wide therapeutic window.

Robinul

is the brand name

image of different drug pills on a surface

Qbrexza Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Robinul

Glycopyrronium

1961

294

Effectiveness

How Qbrexza Affects Patients

Glycopyrronium is a type of medication typically used to treat long-term breathing problems. It is considered to have fewer side effects than other similar medications, but patients may still experience issues like worsening urinary retention, overheating, and blurry vision.

How Qbrexza works in the body

Glycopyrronium blocks a certain kind of receptor in the body called muscarinic receptors. These receptors are found in the lungs, that help control breathing, and in the mouth, stomach, and sweat glands, that help control saliva and acid production. They also help control heart rate. When glycopyrronium blocks these receptors, it reduces the secretion of saliva, stomach acid, and sweat, and helps to prevent slow heart rates.

When to interrupt dosage

The recommended dosage of Qbrexza is contingent upon the diagnosed condition, such as Peptic Ulcer, Neurological Conditions and Drooling. The quantity of dosage can be found in the table below, contingent upon the delivery process (e.g. Capsule - Respiratory (inhalation) or Aerosol, metered).

Condition

Dosage

Administration

Drooling

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Increased upper airway secretion

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Induction of anesthesia therapy

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Choking

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Bronchitis, Chronic

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Peptic Ulcer

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

General Surgery

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Cerebral Palsy

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Hyperhidrosis disorder

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Oral cavity

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Anticholinergic Syndrome

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Reflex, Trigeminocardiac

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Reflex, Trigeminocardiac

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Chronic Obstructive Pulmonary Disease

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

peripheral muscarinic effects

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

cardiac vagal inhibitory reflexes

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Bodily secretions

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Emphysema

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Neurological Conditions

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Warnings

Qbrexza Contraindications

Condition

Risk Level

Notes

Ulcerative Colitis

Do Not Combine

Uterine Inertia

Do Not Combine

Ulcerative Colitis

Do Not Combine

Myasthenia Gravis

Do Not Combine

Arterial Occlusive Diseases

Do Not Combine

Cardiovascular Physiological Phenomena

Do Not Combine

Pulse Frequency

Do Not Combine

Therapeutic procedure

Do Not Combine

Intestinal Pseudo-Obstruction

Do Not Combine

Open-angle glaucoma

Do Not Combine

Uropathy Obstructive

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Glycopyrronium may interact with Pulse Frequency

There are 20 known major drug interactions with Qbrexza.

Common Qbrexza Drug Interactions

Drug Name

Risk Level

Description

Aclidinium

Major

The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Aclidinium.

Cimetropium

Major

The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Cimetropium.

Eluxadoline

Major

The risk or severity of constipation can be increased when Glycopyrronium is combined with Eluxadoline.

Macimorelin

Major

The therapeutic efficacy of Macimorelin can be decreased when used in combination with Glycopyrronium.

Secretin human

Major

The therapeutic efficacy of Secretin human can be decreased when used in combination with Glycopyrronium.

Qbrexza Toxicity & Overdose Risk

Overdosing on Chlorpromazine may cause flushing, fever, rapid heartbeat, constipation, difficulty urinating, trouble seeing close up, light sensitivity, dilated pupils, nausea, vomiting, dizziness, and feeling faint. Treatment includes providing supportive care and potentially using a catheter for urinary retention or providing cardiovascular support, airway maintenance, ventilation, or neostigmine. The lowest toxic dose of Chlorpromazine in mice is 570 mg/kg and in rats is 709 mg/kg, while the intraperitoneal LD50 in mice is 90 mg/kg and in rats is 196 mg/kg

image of a doctor in a lab doing drug, clinical research

Qbrexza Novel Uses: Which Conditions Have a Clinical Trial Featuring Qbrexza?

164 active trials are currently underway to assess the potential of Qbrexza in treating Chronic Obstructive Pulmonary Disease (COPD), modulating cardiac vagal inhibitory reflexes and aiding General Surgery.

Condition

Clinical Trials

Trial Phases

Chronic Obstructive Pulmonary Disease

77 Actively Recruiting

Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4

Choking

4 Actively Recruiting

Not Applicable

General Surgery

2 Actively Recruiting

Not Applicable

Hyperhidrosis disorder

0 Actively Recruiting

Increased upper airway secretion

0 Actively Recruiting

Anticholinergic Syndrome

0 Actively Recruiting

Induction of anesthesia therapy

0 Actively Recruiting

Reflex, Trigeminocardiac

0 Actively Recruiting

Emphysema

4 Actively Recruiting

Phase 2, Not Applicable

Oral cavity

0 Actively Recruiting

peripheral muscarinic effects

0 Actively Recruiting

Reflex, Trigeminocardiac

0 Actively Recruiting

Drooling

0 Actively Recruiting

Neurological Conditions

1 Actively Recruiting

Not Applicable

Bronchitis, Chronic

0 Actively Recruiting

cardiac vagal inhibitory reflexes

0 Actively Recruiting

Peptic Ulcer

0 Actively Recruiting

Bodily secretions

0 Actively Recruiting

Cerebral Palsy

0 Actively Recruiting

Qbrexza Reviews: What are patients saying about Qbrexza?

5

Patient Review

12/17/2019

Qbrexza for Excessive Sweating of the Armpit

This cleansing method has been working great for me. I don't use it every day, but rather every few days as needed. This has helped to avoid any negative side effects.

5

Patient Review

12/12/2019

Qbrexza for Excessive Sweating of the Armpit

This treatment is effective and quick-working. I noticed results after only a couple of days, with no negative side effects.

4.3

Patient Review

8/4/2019

Qbrexza for Excessive Sweating of the Armpit

I've been using this product for a while and it's helped me a lot. I would recommend washing your hands thoroughly after application to avoid any negative side effects. The only downside is that it seems to be slowly becoming less effective over time, which is concerning.

4

Patient Review

6/11/2019

Qbrexza for Excessive Sweating of the Armpit

This product is effective, but the side effects are really tough to deal with. My mouth and nose are so dry that I can barely stand it. Everything tastes horrible, and now I'm constipated on top of everything else. If you can stomach the side effects, this might be a good option for you. But personally, I'd rather try something else.

3.7

Patient Review

8/5/2019

Qbrexza for Excessive Sweating of the Armpit

I didn't like this treatment because it caused really bad dry mouth. It was so uncomfortable and made it hard to eat or talk. The only plus side is that it helped keep my underarms dry.

3

Patient Review

6/7/2019

Qbrexza for Excessive Sweating of the Armpit

The side effects were so bad that I only ended up using it once. My mouth was extremely dry, making it hard to swallow or talk. I also had urinary retention and difficulty urinating. It's a plus that I didn't sweat that day, but the other problems weren't worth it.

3

Patient Review

11/21/2019

Qbrexza for Excessive Sweating of the Armpit

My son experienced a lot of the listed side effects after using this treatment for over a month. They were especially severe in regards to his vision. I contacted the company and they were no help whatsoever.

2.3

Patient Review

8/11/2020

Qbrexza for Excessive Sweating of the Armpit

After only two days of using this product, I started getting nosebleeds from dried-out sinuses. My hands and lips were also extremely dry and swollen. So, I stopped the treatment right away and asked my doctor for an alternative called Mira dry.

1

Patient Review

5/22/2019

Qbrexza for Excessive Sweating of the Armpit

I cannot recommend miradry enough! It's been life-changing for me. I used to have such bad underarm sweating, and since my dermatologist started using it on me, I haven't had any problems at all.

1

Patient Review

7/25/2019

Qbrexza for Excessive Sweating of the Armpit

Though this product did as it said and took away all sweat from my body, the side effects are not worth it. I felt nauseous, had dry mouth and nose, blurred vision, and felt faint constantly. Do not recommend.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about qbrexza

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can you use deodorant while using Qbrexza?

"You can only use deodorant once Qbrexza has dried completely."

Answered by AI

How long does it take Qbrexza to work?

"When will Qbrexza start to work?

Qbrexza will start to work within one to 1.5 hours of application. You may see an improvement in your sweating symptoms after just one week of using the product."

Answered by AI

How long should I use Qbrexza for?

"The studies found that Qbrexza wipes improved "sweating severity" by 25% to 30% (compared to 4% to 5% with placebo), and that measured sweat volume was reduced by 50% or more (in most patients.)"

Answered by AI

Do you need a prescription for Qbrexza?

"Qbrexza is a medication used to treat excessive underarm sweating. It is a topical anticholinergic medicine that is applied to the skin. It is for use in adults and children 9 years of age and older."

Answered by AI

Clinical Trials for Qbrexza

Image of University of Utah South Jordan Health Center - Endoscopy in South Jordan, United States.

Supplemental Oxygen for Apnea During Colonoscopy

18+
All Sexes
South Jordan, UT

This study will compare apnea and oxygen desaturation events among various methods of supplemental oxygen delivery during procedural sedation in colonoscopy patients. The goals of the study are to track apnea (10 or more seconds without respiration) and oxygen desaturation (hemoglobin oxygen saturation less than 90%) events in colonoscopy patients receiving one of three different methods of supplemental oxygen administration. The first method is standard-of-care continuous flow oxygen therapy, where a constant flow of oxygen is administered through a nasal cannula or oxygen mask. The second method is synchronized flow oxygen therapy. This is a delivery method implemented in an FDA-cleared medical device (Sovant, Dynasthetics LLC) which delivers variable-volume oxygen pulses only as the patient inhales. The delivered oxygen pulses are commensurate to the set flow rate and the patient's respiratory rate. The third method is continuous positive airway pressure therapy (CPAP), where non-invasive pressure support is given to the patient's airway to help keep their airway open. The hypothesis being tested is that synchronized flow delivery and CPAP therapy will demonstrate reductions in apnea and oxygen desaturation events compared to traditional continuous flow oxygen therapy.

Waitlist Available
Has No Placebo

University of Utah South Jordan Health Center - Endoscopy

Kai Kuck, PhD

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+
All Sexes
Stanford, CA

Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.

Waitlist Available
Has No Placebo

Stanford University

Jeff Swigris, DO, MS

Minnesota Health Solutions

Have you considered Qbrexza clinical trials?

We made a collection of clinical trials featuring Qbrexza, we think they might fit your search criteria.
Go to Trials

Have you considered Qbrexza clinical trials?

We made a collection of clinical trials featuring Qbrexza, we think they might fit your search criteria.
Go to Trials
Image of University of Massachusetts Chan Medical School in Worcester, United States.

Paramedic Evaluation for Chronic Obstructive Pulmonary Disease

18+
All Sexes
Worcester, MA

Chronic Obstructive Pulmonary Disease (COPD) is a serious lung condition that affects millions of people in the United States. Each year, it leads to about 150,000 deaths, nearly 900,000 emergency room visits, and 700,000 hospital stays. When COPD symptoms suddenly get worse-called an exacerbation-it can seriously harm a person's quality of life and often requires emergency care. Treating these flare-ups early can help prevent hospital visits, but right now, there aren't many good ways to make sure people get care quickly. Mobile Integrated Health (MIH) programs send specially trained paramedics, guided remotely by doctors, to care for patients in their homes. This approach could help people with COPD get faster, more effective care without needing to go to the hospital. In this project, the investigators are testing a new program called PEACE (Paramedic Evaluation for Acute COPD Exacerbation). The PEACE program sends community paramedics to patients' homes-when needed and in partnership with their regular doctors-to manage worsening COPD symptoms early. The study team will adapt the PEACE program to meet the needs of adults living at home with moderate to severe COPD, gather feedback from patients and healthcare providers, and run a small pilot study to see if the program is practical and helpful.

Recruiting
Has No Placebo

University of Massachusetts Chan Medical School

Laurel O'Connor, MD, MSc

Have you considered Qbrexza clinical trials?

We made a collection of clinical trials featuring Qbrexza, we think they might fit your search criteria.
Go to Trials